BTG Specialty Pharmaceuticals, a division of Boston Scientific, provides rescue medicines to treat patients for whom there are limited treatment options. We are dedicated to the development, manufacture, and commercialization of quality medicines that make a real difference to patients and their families.
We are committed to supporting independent research in the form of Investigator Initiated and Sponsored (IIS) studies that further the understanding of diseases and their treatment with the ultimate goal of helping patients. Our support of IISs provides a unique opportunity for physicians to explore areas of mutual scientific interest and build scientific knowledge of disease management and the role that our therapies can play.
Initial data from two cohorts of an IIS study exploring the planned use of Voraxaze® (glucarpidase) following high dose methotrexate administered in patients with central nervous system lymphoma are being presented at the 2020 Society for Neuro-Oncology.
Dr. Lauren Schaff, principle investigator, will be here to answer any questions about her research study on Saturday November 21 at 10-11am EST.
Link to poster: [insert link when available]
Link to platform: [insert link when available]
For more information about the ongoing study please visit click here.